The study is ongoing and preliminary results have been published in the New England Journal of Medicine.The full analysis of the COMET-ICE trial was published in JAMA and it showed that sotrovimab reduced risk of hospitalization for more than 24 hours or death by 79% compared to placebo (1% for sotrovoimab group and 6% for the placebo group). The trial involved 1057 participants and took place before the omicron variant was prevalent. Manufacturing
Sotrovimab is a biologic product which takes six months to manufacture in living cells. It is produced in Chinese hamster ovary cells. At product launch in May 2021, sotrovimabs active pharmaceutical ingredient was produced by WuXi Biologics in China and sent to a GlaxoSmithKline plant in Parma, Italy for further processing into the finished product. In January 2022, the spread of the SARS-CoV-2 Omicron variant began to render other monoclonal antibodies obsolete and caused global demand for sotrovimab to skyrocket. In response, Vir and GlaxoSmithKline announced they were working with Samsung Biologics on manufacturing sotrovimab at an additional site in South Korea. Society and culture
Economics
In 2021, the United States government agreed to purchase 1.5 million doses of the drug at $2,100 per dose. Legal status
In May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) completed its review on the use of sotrovimab for the treatment of COVID-19.
13.5 and 18 g/dl are the lower and upper limits of the acceptable range. For women, 12.0 to 15.5 grams per deciliter 12 and 16 g/dl are the lower and upper limits of the acceptable range. Treatment
High hemoglobin levels are a rare occurrence but is usually treated as a symptom for an underlying disease. Consulting a doctor is the best treatment, so they can diagnose your illness and give a recommended treatment plan to lower hemoglobin levels back to normal. See also
Coagulation
Blood diseases
Methemoglobinemia, an abnormal amount of methemoglobin which is carrying oxygen but unable to release it effectively to body tissues, is produced. References
"Hemolytic Anemia". University of Virginia Health System. Retrieved 2009-05-01.